指南与共识烧伤创面修复

烧伤酶性清创(菠萝蛋白酶)欧洲共识指南更新

Eschar removal by bromelain based enzymatic debridement (Nexobrid®) in burns: European consensus guidelines update.
指南 / 共识 · Burns · 2020-03-30

欧洲12中心多学科专家组基于1232例酶性清创病例更新2019版共识,形成43条推荐,42条达成共识(97.7%),并提出按清创时机分为即刻/极早期(≤12 h)、早期(12-72 h)和延迟(>72 h)的分类。

要点

  • 酶性清创最适合混合模式的真皮中层至深层烧伤。
  • 推荐按时机分类:即刻/极早期(≤12 h)、早期(12-72 h)、延迟(>72 h)。
  • 共识覆盖适应证、疼痛麻醉、大面积处理、植皮及瘢痕修订等。

核心结论

  • 更新版指南细化了酶性清创的适应证、应用及干预后管理推荐。
  • 43条声明中42条达成共识(97.7%),共识度很高。

研究设计与样本

  • 欧洲12中心整形外科与烧伤护理专家组成多专业专家组。
  • 基于同行评议文献和临床相关性制定共识声明。
  • 采用改良Willy和Stellar一致性算法,每条声明至少80%同意视为共识。
  • 汇总专家组在欧洲治疗的1232例酶性清创病例(2017版为500例)。

主要发现

  • 共形成43条声明,覆盖适应证、疼痛管理、麻醉、大面积治疗、应用时机、准备与操作、干预后创面管理、植皮、结局、瘢痕与修订、成本效益、患者视角、物流及培训策略。
  • 引入清创时机分类:即刻/极早期(≤12 h)、早期(12-72 h)、延迟(>72 h)。

关键数值与推荐

  • 酶性清创最佳适应证为混合模式的真皮中层至深层烧伤。
  • 共识阈值:每条声明至少80%同意。
  • 时机分类:即刻/极早期≤12 h,早期12-72 h,延迟>72 h。
  • 共识达成率:42/43条(97.7%)。

临床怎么用

  • 按时机分类(≤12 h、12-72 h、>72 h)选择酶性清创应用窗口。
  • 参照43条推荐规范适应证、疼痛麻醉、大面积处理及干预后创面管理与植皮。
  • 借鉴共识细节以在更多国家(如美国)成功实施酶性清创并避免陷阱。

局限性

  • 专家组汇总的1232例为临床经验病例,非前瞻性对照试验。
  • 共识基于同行评议文献和临床相关性,未报告系统检索策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Bromelain-based Enzymatic Debridement has been introduced as an additional concept to the burn surgeon's armamentarium and is best indicated for mid-to deep dermal burns with mixed patterns. Increasing evidence has been published focusing on special regions and settings as well as on limitations of Enzymatic Debridement to improve patient care. To better guide Enzymatic Debridement in view of the increasing experience, there is a need to update the formerly published consensus guidelines with user-orientated recommendations, which were last produced in 2017. METHODS: A multi-professional expert panel of plastic surgeons and burn care specialists from twelve European centers was convened, to assist in developing current recommendations for best practices with use of Enzymatic Debridement. Consensus statements were based on peer-reviewed publications and clinical relevance, and topics for re-evaluation and refinement were derived from the formerly published European guidelines. For consensus agreement, the methodology employed was an agreement algorithm based on a modification of the Willy and Stellar method. For this study on Enzymatic Debridement, consensus was considered when there was at least 80 % agreement to each statement. RESULTS: The updated consensus guidelines from 2019 refer to the clinical experience and practice patterns of 1232 summarized patient cases treated by the panelists with ED in Europe (2017: 500 cases), reflecting the impact of the published recommendations. Forty-three statements were formulated, addressing the following topics: indications, pain management and anesthesia, large surface treatment, timing of application for various indications, preparation and application, post-interventional wound management, skin grafting, outcome, scar and revision management, cost-effectiveness, patient´s perspective, logistic aspects and training strategies. The degree of consensus was remarkably high, with consensus in 42 out of 43 statements (97.7%). A classification with regard to timing of application for Enzymatic Debridement was introduced, discriminating immediate/very early (≤12 h), early (12-72 h) or delayed (>72 h) treatment. All further recommendations are addressed in the publication. CONCLUSIONS: The updated guidelines in this publication represent further refinement of the recommended indication, application and post-interventional management for the use of ED. The published statements contain detailed, user-orientated recommendations aiming to align current and future users and prevent pitfalls, e.g. for the successful implementation of ED in further countries like the USA. The significance of this work is reflected by the magnitude of patient experience behind it, larger than the total number of patients treated in all published ED clinical trials.

来源:Burns,查看原文。版权归原作者所有。

引用

  1. Hirche C, Kreken Almeland S, Dheansa B, et al. Eschar removal by bromelain based enzymatic debridement (Nexobrid®) in burns: European consensus guidelines update. Burns. 2020. PMID: 32241591. doi:10.1016/j.burns.2020.03.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。